Type 2 Diabetes: An Expanded View of Pathophysiology and Therapy

References

• . Department of Health and Human Services, Centers for Disease Control and Prevention. National diabetes fact sheet: general information. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2008
   Google Scholar
• . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977–986
   PubMed Web of Science ®Google Scholar
• . Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73–78
   PubMed Web of Science ®Google Scholar
• . Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–234
   PubMed Web of Science ®Google Scholar
• . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589
   PubMed Web of Science ®Google Scholar
• . Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–591
   PubMed Web of Science ®Google Scholar
• . Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291(3):335–342
   PubMed Web of Science ®Google Scholar
• . Phillips LS, Branch WT, Cook CB, . Clinical inertia. Ann Intern Med. 2001;135(9):825–834
   PubMed Web of Science ®Google Scholar
• . Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectrum. 2004;17(3):183–190
   Google Scholar
• . Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev. 1998;19(4):477–490
   PubMed Web of Science ®Google Scholar
• . Jallut D, Golay A, Munger R, . Impaired glucose tolerance and diabetes in obesity: a 6-year follow-up study of glucose metabolism. Metabolism. 1990;39(10):1068–1075
   PubMed Web of Science ®Google Scholar
• . Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA; San Antonio Metabolism Study.Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia. 2004;47(1):31–39
   PubMed Web of Science ®Google Scholar
• . Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102–110
   PubMed Web of Science ®Google Scholar
• . Reaven E, Wright D, Mondon CE, Solomon R, Ho H, Reaven GM. Effect of age and diet on insulin secretion and insulin action in the rat. Diabetes. 1983;32(2):175–180
   PubMed Web of Science ®Google Scholar
• . Elahi D, Muller DC, Egan JM, Andres R, Veldhuist J, Meneilly GS. Glucose tolerance, glucose utilization and insulin secretion in ageing. Novartis Found Symp. 2002;242:222–242
   PubMedGoogle Scholar
• . DeFronzo RA. Glucose intolerance and aging. Diabetes Care. 1981;4(4):493–501
   PubMed Web of Science ®Google Scholar
• . Lyssenko V, Lupi R, Marchetti P, . Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest. 2007;117(8):2155–2163
   PubMed Web of Science ®Google Scholar
• . Saxena R, Gianniny L, Burtt NP, . Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes. 2006;55(10):2890–2895
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism. 1989;38(4):387–395
   PubMed Web of Science ®Google Scholar
• . Kashyap S, Belfort R, Gastaldelli A, . A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes. 2003;52(10):2461–2474
   PubMed Web of Science ®Google Scholar
• . Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest. 1987;80(4):1037–1044
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988;37(6):667–687
   PubMed Web of Science ®Google Scholar
• . Cusi K, Maezono K, Osman A, . Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest. 2000;105(3):311–320
   PubMed Web of Science ®Google Scholar
• . Baron AD, Schaeffer L, Shragg P, Kolterman OG. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes. 1987;36(3):274–283
   PubMed Web of Science ®Google Scholar
• . Groop LC, Bonadonna RC, DelPrato S, . Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest. 1989;84(1):205–213
   PubMed Web of Science ®Google Scholar
• . Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A. 1994;91(23):10878–10882
   PubMed Web of Science ®Google Scholar
• . Boden G. Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. Exp Clin Endocrinol Diabetes. 2003;111(3):121–124
   PubMed Web of Science ®Google Scholar
• . Boden G. Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Proc Assoc Am Physicians. 1999;111(3):241–248
   PubMedGoogle Scholar
• . Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest. 2002;32( suppl 3):14–23
   PubMed Web of Science ®Google Scholar
• . Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004;287(2):E199–E206
   PubMed Web of Science ®Google Scholar
• . Toft-Nielsen MB, Damholt MB, Madsbad S, . Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86(8):3717–3723
   PubMed Web of Science ®Google Scholar
• . Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7–37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest. 1987;79(2):616–619
   PubMed Web of Science ®Google Scholar
• . Göke R, Wagner B, Fehmann HC, Göke B. Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas. Res Exp Med (Berl). 1993;193(2):97–103
   PubMedGoogle Scholar
• . Holst JJ. Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential. Trends Endocrinol Metab. 1999;10(6):229–235
   PubMed Web of Science ®Google Scholar
• . Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7–36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab. 1996;81(1):327–332
   PubMed Web of Science ®Google Scholar
• . Young AA, Gedulin BR, Rink TJ. Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism. 1996;45(1):1–3
   PubMed Web of Science ®Google Scholar
• . Turton MD, O'Shea D, Gunn I, . A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379(6560):69–72
   PubMed Web of Science ®Google Scholar
• . DeFronzo F, Ferrannini E, Wahren J, Felig P. Lack of a gastrointestinal mediator of insulin action in maturity-onset diabetes. Lancet. 1978;2(8099):1077–1079
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Ferrannini E, Hendler R, Wahren J, Felig P. Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange. Proc Natl Acad Sci U S A. 1978;75(10):5173–5177
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Ferrannini E, Hendler R, Felig P, Wahren J. Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man. Diabetes. 1983;32(1):35–45
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Gunnarsson R, Bjorkman O, Olsson M, Wahren J. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest. 1985;76(1):149–155
   PubMed Web of Science ®Google Scholar
• . Ferrannini E, Simonson DC, Katz LD, . The disposal of an oral glucose load in patients with non-insulin-dependent diabetes. Metabolism. 1988;37(1):79–85
   PubMed Web of Science ®Google Scholar
• . Unger J, Parkin C. Appropriate, timely and rational treatment of type 2 diabetes mellitus: Meeting the challenges of primary care. Insulin. 2009;4:144–157
   Google Scholar
• . Nathan DM, Buse JB, Davidson MB, ; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795
   PubMed Web of Science ®Google Scholar
• . Parkin CG, Davidson JA. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2007;30(1):192–193
   PubMed Web of Science ®Google Scholar
• . Cryer PE. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2007;30(1):190–192
   PubMed Web of Science ®Google Scholar
• . Porta M, Trento M. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2007;30(1):193
   PubMedGoogle Scholar
• . Mannucci E, Monami M, Pala L, . Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2007;30(1):193–194
   PubMedGoogle Scholar
• . Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators.The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080–3086
   PubMed Web of Science ®Google Scholar
• . Kahn SE, Haffner SM, Heise MA, ; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–2443
   PubMed Web of Science ®Google Scholar
• . Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19( suppl):830
   Web of Science ®Google Scholar
• . ; ADVANCE Collaborative GroupPatel A, MacMahon S, Chalmers J, . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2009. Diabetes Care. 2009;32( suppl 1):S13–S61
   PubMed Web of Science ®Google Scholar
• . ; American Diabetes AssociationBantle JP, Wylie-Rosett J, Albright AL, . Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008;31( suppl 1):S61–S78
   PubMed Web of Science ®Google Scholar
• . Parkin CG, Hinnen D, Valentine D, . AADE Guidelines for the Practice of Diabetes Self-Management Education and Training (DSME/T). Chicago, IL: American Association of Diabetes Educators; 2009
   Google Scholar
• . Boulé NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001;286(10):1218–1227
   PubMed Web of Science ®Google Scholar
• . Harris MD. Psychosocial aspects of diabetes with an emphasis on depression. Curr Diab Rep. 2003;3(1):49–55
   PubMedGoogle Scholar
• . Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24(6):1069–1078
   PubMed Web of Science ®Google Scholar
• . Lawlor DA, Hopker SW. The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials. BMJ. 2001;322(7289):763–767
   PubMed Web of Science ®Google Scholar
• . Klein S, Sheard NF, Pi-Sunyer X, ; North American Association for the Study of Obesity; American Society for Clinical Nutrition. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care. 2004;27(8):2067–2073
   PubMed Web of Science ®Google Scholar
• . Albright A, Franz M, Hornsby G, . American College of Sports Medicine position stand. Exercise and type 2 diabetes. Med Sci Sports Exerc. 2000;32(7):1345–1360
   PubMed Web of Science ®Google Scholar
• . Mulcahy K, Maryniuk M, Peeples M, . Diabetes self-management education core outcomes measures. Diabetes Educ. 2003;29(5):768–770, 773–784, 787–788
   PubMed Web of Science ®Google Scholar
• . Parkin C, Owens DR, Gagliardino JJ, Colagiuri S. Self-monitoring. Abstract presented at: International Diabetes Federation 2009 20th World Congress; Montreal, Canada; October 18–22, 2009
   Google Scholar
• . Parkin CG, Davidson JA. Value of self-monitoring of blood glucose pattern analysis in improving diabetes outcomes. J Diab Sci and Tech. 2009;3(3):500–508
   PubMedGoogle Scholar
• . Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs. 2003;63(18):1879–1894
   PubMed Web of Science ®Google Scholar
• . Palamara KL, Mogul HR, Peterson SJ, Frishman WH. Obesity: new perspectives and pharmacotherapies. Cardiol Rev. 2006;14(5):238–258
   PubMedGoogle Scholar
• . Rains SG, Wilson GA, Richmond W, Elkeles RS. The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy. J R Soc Med. 1989;82(2):93–94
   PubMed Web of Science ®Google Scholar
• . Knowler WC, Barrett-Connor E, Fowler SE, ; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403
   PubMed Web of Science ®Google Scholar
• . Jellinger PS. Metabolic consequences of hyperglycemia and insulin resistance. Clin Cornerstone. 2007;8( suppl 7):S30–S42
   Google Scholar
• . de Vegt F, Dekker JM, Jager A, . Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA. 2001;285(16):2109–2113
   PubMed Web of Science ®Google Scholar
• . ; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial InvestigatorsGerstein HC, Yusuf S, Bosch J, . Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368(9541):1096–1105
   PubMed Web of Science ®Google Scholar
• . DeFronzo, R. ACTos NOW for the prevention of diabetes (ACT NOW) study. Presented at: American Diabetes Association 68th Scientific Sessions; San Francisco, CA; September 6–9, 2008
   Google Scholar
• . Barnett AH. Insulin-sensitizing agents–thiazolidinediones (glitazones). Curr Med Res Opin. 2002;18( suppl 1):S31–S39
   PubMedGoogle Scholar
• . Scheen A. Glitazones and weight gain [in French]. Ann Endocrinol (Paris). 2002;63(2 pt 2):1S41–1S44
   PubMed Web of Science ®Google Scholar
• . Zinman B, Hoogwerf BJ, Durán GS, . The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007;146(7):477–485
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Blonde L, Braithwaite SS, ; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13( suppl 1):1–68
   PubMedGoogle Scholar
• . Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–1705
   PubMed Web of Science ®Google Scholar
• . Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153–165
   PubMed Web of Science ®Google Scholar
• . Farilla L, Bulotta A, Hirshberg B, . Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144(12):5149–5158
   PubMed Web of Science ®Google Scholar
• . Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem. 2003;278(1):471–478
   PubMed Web of Science ®Google Scholar
• . Nystrom T, Gutniak MK, Zhang Q, . Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287(6):E1209–E1215
   PubMed Web of Science ®Google Scholar
• . Nikolaidis LA, Mankad S, Sokos GG, . Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109(8):962–965
   PubMed Web of Science ®Google Scholar
• . Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12(9):694–699
   PubMed Web of Science ®Google Scholar
• . Sokos GG, Bolukoglu H, German J, . Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007;100(5):824–829
   PubMed Web of Science ®Google Scholar
• . Stonehouse A, Okerson T, Kendall D, Maggs D. Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Curr Diabetes Rev. 2008;4(2):101–109
   PubMedGoogle Scholar
• . Blonde L, Klein EJ, Han J, . Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8(4):436–447
   PubMed Web of Science ®Google Scholar
• . Klonoff DC, Buse JB, Nielsen LL, . Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24(1):275–286
   PubMed Web of Science ®Google Scholar
• . Drucker DJ, Buse JB, Taylor K, ; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240–1250
   PubMed Web of Science ®Google Scholar
• . Bergenstal RM, Kim T, Trautmann M, Zhuang D, Okerson T, Taylor K. Exenatide once weekly elicited improvements in blood pressure and lipid profile over 52 weeks in patients with type 2 diabetes. Circulation. 2008;118( suppl 1):1086
   Web of Science ®Google Scholar
• . Garber A, Henry R, Ratner R, ; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473–481
   PubMed Web of Science ®Google Scholar
• . Buse JB, Rosenstock J, Sesti G, ; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47
   PubMed Web of Science ®Google Scholar
• . Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25(4):1019–1027
   PubMed Web of Science ®Google Scholar
• . Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol. 2009;160(6):909–917
   PubMed Web of Science ®Google Scholar
• . Triplitt C, McGill JB, Porte D Jr, Conner CS. The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomes. J Manag Care Pharm. 2007;13(9 suppl C):S2–S16
   Web of Science ®Google Scholar
• . McGill JB. Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes. Postgrad Med. 2009;121(1):46–58
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Hissa MN, Garber AJ; Saxagliptin 014 Study Group.The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care. 2009;32(9):1649–1655
   PubMed Web of Science ®Google Scholar
• . Ahrén B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab. 2007;21(4):517–533
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24(10):2943–2952
   PubMed Web of Science ®Google Scholar
• . Cervera A, Wajcberg E, Sriwijitkamol A, . Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab. 2008;294(5):E846–E852
   PubMed Web of Science ®Google Scholar
• . Göke R, Fehmann HC, Linn T, . Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 1993;268(26):19650–19655
   PubMed Web of Science ®Google Scholar
• . Watson WA, Litovitz TL, Rodgers GC Jr, . 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 2005;23(5):589–666
   PubMed Web of Science ®Google Scholar
• . Krentz AJ. Comparative safety of newer oral antidiabetic drugs. Expert Opin Drug Saf. 2006;5(6):827–834
   PubMed Web of Science ®Google Scholar
• . Nielsen LL. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov Today. 2005;10(10):703–710
   PubMed Web of Science ®Google Scholar
• . Marre M, Shaw J, Brändle M, . Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268–278
   PubMed Web of Science ®Google Scholar
• . Prazak R, Sabine R, Ellingsgaard H, Knudsen L, Donath M. Liraglutide induces cell proliferation and protects from interleukin-1 beta-induced beta cell apoptosis in human islets. Diabetes. 2008;57( suppl 1):A440–A441
   PubMed Web of Science ®Google Scholar
• . Bergenstal R, Kim T, Yan P, . Exenatide once weekly improved cardiometabolic risk factors in subjects with type 2 diabetes during one year of treatment. Diabetes. 2009;58( suppl 2):A43
   Web of Science ®Google Scholar
• . Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab. 2003;88(2):531–537
   PubMed Web of Science ®Google Scholar
• . Unger J. Managing type 2 diabetes in adults. In: Diabetes Management in Primary Care. Philadelphia, PA: Lippincott, Williams & Wilkins; 2007:118–191
   Google Scholar
• . Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and non-fatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2003;(2):CD002967
   Google Scholar
• . Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group.Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia. 2004;47(6):969–975
   PubMed Web of Science ®Google Scholar
• . Schwartz AV. TZDs and bone: a review of the recent clinical evidence. PPAR Res. 2008:297–893
   Google Scholar